Results 81 to 90 of about 21,874 (160)

[Retracted] Antitumor activity of NRC‑AN‑019 in a pre‑clinical breast cancer model. [PDF]

Int J Oncol
Gondi CS, Gorantla B, Rao AKSB, Amala K, Naidu MUR, Jogi KV, Ramana GV, Myneni PC, Junnarkar A, Rao JS.   +9 more
europepmc   +1 more source

Signal mining and safety profile analysis of lapatinib: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. [PDF]

J Pharm Policy Pract
Cerbito E, Diab MI, Alhoshani A, Maayah ZH.   +3 more
europepmc   +1 more source

Benchmarking the Ligand-HER2 Interactions Using Machine Learning and Molecular Dynamics Simulations. [PDF]

ACS Omega
Truong DT, Dao QT, Tran TTM, Nguyen NH, Nguyen-Thao MK, Nam NH, Do TMD, Nguyen MT.   +7 more
europepmc   +1 more source

BDDN: bayesian dynamic differential network analysis in cancer proteomics. [PDF]

BMC Bioinformatics
Kim J, Lee D, Park J, Jin IH, Ha MJ.
europepmc   +1 more source

Anti-HER2-targeted therapies: effects on human <i>in vitro</i> blood-brain barrier models. [PDF]

Front Drug Deliv
Curtaz CJ, Gebert R, Wöckel A, Meybohm P, Burek M.   +4 more
europepmc   +1 more source

Epidermal Growth Factor Receptor/KIT-Linked Proliferative Bias in Normal Breast Lobules from Matched Non-Hispanic Black and White Women Is Rapidly Reversible by Receptor Tyrosine Kinase Inhibition. [PDF]

Am J Pathol
Ogony JW, Cruz-Reyes N, Pacheco-Spann L, Arnold A, McLaughlin S, Degnim AC, Winham SJ, Sherman ME, Radisky DC.   +8 more
europepmc   +1 more source

Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR Inhibition. [PDF]

Cell Oncol (Dordr)
van der Noord VE, McLaughlin RP, Karuntu JS, He J, Timmermans AM, Basnet SKC, Long Y, Diab SAH, Tadesse S, Proost N, van Gerwen B, Siteur B, van de Ven M, Pont C, Le Dévédec SE, Martens JWM, Wang S, Zhang Y, van de Water B.   +18 more
europepmc   +1 more source

HER2-driven mammary tumorigenesis enhances bioenergetics despite reductions in mitochondrial content. [PDF]

Elife
Frangos SM, Brunetta HS, Wang D, Jabile MJT, Jeffries LM, Mencfeld G, Ma DWL, Muller WJ, Khursigara CM, Fisher-Wellman KH, Petrik J, Steinberg GR, Holloway GP.   +12 more
europepmc   +1 more source

Advances in the study of pyrotinib for the treatment of HER2-positive breast cancer. [PDF]

Breast Cancer Res
Li Y, Wang W, Liang Y, Lai H, Mi K, Zhang P, Zhang J, Wang Y.   +7 more
europepmc   +1 more source

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer. [PDF]

Curr Treat Options Oncol
Weiner-Gorzel K, McSorley L, Walshe JM.
europepmc   +1 more source